Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 4,226 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable Placebo Clear all

Conditions: Cervical Dystonia
Interventions: DaxibotulinumtoxinA for injection, Placebo; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib, Dupilumab, Placebo to dupilumab, Placebo to upadacitinib; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 52
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 43 more

Conditions: Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Interventions: PQ Grass, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 33
States / cities: Centennial, Colorado • Denver, Colorado • Lexington, Kentucky + 27 more

Conditions: Pre Diabetes, Postpartum Disorder
Interventions: Semaglutide Pen Injector [Ozempic], Placebo semaglutide pen injector; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Myocardial Infarction
Interventions: Tocilizumab, Placebo; Drug
Lead sponsor: Keesler Air Force Base Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Keesler Air Force Base, Mississippi

Conditions: Crohn's Disease
Interventions: Certolizumab pegol, Azathioprine; Biological · Drug
Lead sponsor: Gastroenterology Research of America; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Moderate to Severe Allergic Asthma
Interventions: CYT003, Placebo; Biological
Lead sponsor: Cytos Biotechnology AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more

Conditions: Inflammatory Response
Interventions: Pneumovax 23, Typhim VI, Saline; Drug · Other
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions: Octreotide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neuropathic Pain
Interventions: ASCT-83, Placebo; Drug
Lead sponsor: Alcamena Stem Cell Therapeutics; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Restrictive Burn Scars of Joint Area
Interventions: Autologous Human Fibroblasts (Isolagen TherapyTM), Placebo; Biological
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • East Meadow, New York • Galveston, Texas

Conditions: Subcutaneous Fat
Interventions: CBL-514 Injection, 0.9% Sodium Chloride; Drug · Other
Lead sponsor: Caliway Biopharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 11
States / cities: Encinitas, California • West Palm Beach, Florida • Chicago, Illinois + 8 more

Conditions: Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
Interventions: Placebo, PIZV; Drug · Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 271 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more

Conditions: Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
Interventions: REMD-477, Placebo Subcutaneous injection; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Lung Transplant
Interventions: Tocilizumab, Placebo for Tocilizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more

Conditions: ACE Inhibitor Induced Angioedema
Interventions: ecallantide 60 mg, ecallantide 30 mg, ecallantide 10 mg, placebo, placebo match for 30 mg ecallantide arm, placebo match for 10 mg ecallantide arm; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 39
States / cities: Montgomery, Alabama • Colton, California • Los Angeles, California + 33 more

Conditions: Type 2 Diabetes
Interventions: placebo, exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 40
States / cities: Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more

Conditions: Tinnitus
Interventions: AM-101 0.81 mg/mL, Placebo; Drug
Lead sponsor: Auris Medical, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Gainsville, Florida • Kansas City, Kansas • Louisville, Kentucky + 2 more

Conditions: Psoriatic Arthritis
Interventions: Secukinumab; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 22
States / cities: Upland, California • Aurora, Colorado • Denver, Colorado + 16 more

Conditions: Post-traumatic Stress Disorder
Interventions: Stellate Ganglion Block, Sham Stellate Ganglion Block; Procedure
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Long Beach, California • Tampa, Florida • Minneapolis, Minnesota + 3 more

Conditions: Acute Intermittent Porphyria, Hereditary Coproporphyria, Variegate Porphyria
Interventions: Hemin for injection, Placebo; Biological · Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Shivering, Nausea and Vomiting, Postoperative
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer's Disease
Interventions: Placebo, CAD106; Biological
Lead sponsor: Novartis; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 10
States / cities: Costa Mesa, California • Boulder, Colorado • Hollywood, Florida + 7 more

Conditions: Tendinopathy
Interventions: Somatropin, Bacteriostatic saline, Progressive exercise program, Patellar tendon biopsy; Drug · Other · Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Treatment to Regress to Normoglycemia in Women with a Recent History of GDM

Short-Term Application of Tocilizumab Following Myocardial Infarction

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Persistent Readiness Through Early Prediction Immunization Study

Octreotide in Severe Polycystic Liver Disease

Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults

Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

Tocilizumab in Lung Transplantation

Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

Stellate Ganglion Block for PTSD

Panhematin for Prevention of Acute Attacks of Porphyria

Dexmedetomidine After Cesarean for the Treatment of Nausea and Shivering

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients

A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy